BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 27897048)

  • 21. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
    Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
    Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 26. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
    Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
    Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
    Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
    Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
    J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
    Paszkiewicz PJ; Fräßle SP; Srivastava S; Sommermeyer D; Hudecek M; Drexler I; Sadelain M; Liu L; Jensen MC; Riddell SR; Busch DH
    J Clin Invest; 2016 Nov; 126(11):4262-4272. PubMed ID: 27760047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
    Park JH; Geyer MB; Brentjens RJ
    Blood; 2016 Jun; 127(26):3312-20. PubMed ID: 27207800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.
    Xu XJ; Zhao HZ; Tang YM
    Leuk Lymphoma; 2013 Feb; 54(2):255-60. PubMed ID: 22897728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor-derived CD19 chimeric antigen receptor T cells.
    Singh N; Barrett DM
    Curr Opin Hematol; 2015 Nov; 22(6):503-8. PubMed ID: 26457962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.